Sensei Biotherapeutics (SNSE) Q4 2025 earnings summary

Executive summary

• Completed acquisition of Faeth Therapeutics, adding PIKTOR, an all-oral combination targeting the PI3K/AKT/mTOR pathway, as the lead program.

• Secured $200 million in private placement to fund clinical milestones in endometrial and breast cancer.

• Focused on advancing PIKTOR through Phase 2 and planned Phase 1b trials, with topline data expected by year-end 2026.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $21.2 million as of December 31, 2025, down from $41.3 million at year-end 2024.

• R&D expenses decreased to $11.0 million in 2025 from $18.6 million in 2024, mainly due to reduced personnel, facilities, lab, clinical, and manufacturing costs.

• G&A expenses fell to $11.3 million in 2025 from $13.0 million in 2024, reflecting lower personnel costs but higher restructuring and consulting expenses.

• Net loss was $21.1 million ($16.72 per share) for 2025, compared to $30.2 million ($24.01 per share) in 2024.

• Weighted-average shares outstanding were 1,260,772 in 2025 versus 1,255,776 in 2024.

Outlook and guidance

• Topline data from the ongoing Phase 2 trial in advanced endometrial cancer and initiation of the Phase 1b trial in HR+/HER2- advanced breast cancer are both expected by year-end 2026.

• Additional clinical opportunities are being explored in ovarian and lung cancer.